New Oral Anticoagulant Drugs

dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDepartment of Pharmacologyhu_HU
dc.contributor.authorArraf, Nada
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház Központi Aneszteziológiai és Intezív Terápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2019-09-24T11:40:03Z
dc.date.available2019-09-24T11:40:03Z
dc.date.created2019-04-12
dc.description.abstractThrombosis and thromboembolic events are the major cause of mortality and morbidity nowadays.The traditional anticoagulant therapy includes vitamin K antagonists and heparin. However, warfarin's significant disadvantages including the variability in dose-response, the narrow therapeutic index, and the numerous drug and dietary interactions associated with this agent have led to the introduction of the new oral anticoagulants (NOACs).New oral anticoagulants (NOAC) are a group of drugs comprising of direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban and others). NOACs have major pharmacological benefits over warfarin including, much fewer food and drug interactions, having a fixed dose and not requiring frequent monitoring.hu_HU
dc.description.correctorLB
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent44hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/273693
dc.language.isoenhu_HU
dc.subjectThrombosishu_HU
dc.subjectRivaroxaban (Xarelto)hu_HU
dc.subjectApixaban(Eliquis)hu_HU
dc.subjectedoxaban (Savaysa®)hu_HU
dc.subjectNOACshu_HU
dc.subjectAcute Coronary syndromehu_HU
dc.subjectIdarucizumabhu_HU
dc.subjectandexanet alfa (Andexxa)hu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleNew Oral Anticoagulant Drugshu_HU
Fájlok